Neuroendocrine tumors (NETs) are rare tumors that can arise in almost any organ of the body. They show a wide range of characteristics that challenge early diagnosis and require a coordinated multidisciplinary approach. The radiotracers that are mostly used for diagnostic imaging are 68Ga-DOTATATE for somatostatin receptors (SSTR)-expressing tumors and fluorodeoxyglucose (18FDG) for poorly-differentiated cancers. The gold-standard treatment is complete debulk of the primary tumor which is often unfeasible given that 30-70% of NETs are already metastatic when first diagnosed and surgery is no longer an option. Peptide receptor radionuclide therapy (PRRT) is a systemic therapy indicated for NETs characterized by high SSTR expression. To date, a tool for the early detection and treatment of NETs is missing, posing significant challenges for patients and physicians.
The primary goal of this research topic is to provide a valuable collection of cutting-edge research papers in the field of NETs. Precisely, we hope that it will highlight advancements in diagnostic imaging, new biomarkers, radiotracers, NET metabolism, and tumor microenvironment to foster progress toward personalized care for NET patients.
We invite Authors to submit original research articles, comprehensive reviews, case reports, and clinical studies that focus on, but are not limited to, the development of new therapeutic approaches including SSTR-based, targeted therapies, immunotherapies, ATMPs and chimeric antigen receptor (CAR) T cells. We also invite retrospective and prospective comparisons of current lines of therapy, liquid biopsy, diagnostic techniques, radiomics, and their role in monitoring NET progression. To conclude, papers elucidating specific aspects of NET metabolism and tumor microenvironment to drive NET tumorigenesis and resistance to therapy are welcome. We hope this research topic will gather studies featuring the most advanced and promising approaches for NET diagnosis and treatment paving the future of patients’ quality of life.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords:
SSTR, radiotracers, PRRT, metabolism, diagnostics, Liquid-biopsy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Neuroendocrine tumors (NETs) are rare tumors that can arise in almost any organ of the body. They show a wide range of characteristics that challenge early diagnosis and require a coordinated multidisciplinary approach. The radiotracers that are mostly used for diagnostic imaging are 68Ga-DOTATATE for somatostatin receptors (SSTR)-expressing tumors and fluorodeoxyglucose (18FDG) for poorly-differentiated cancers. The gold-standard treatment is complete debulk of the primary tumor which is often unfeasible given that 30-70% of NETs are already metastatic when first diagnosed and surgery is no longer an option. Peptide receptor radionuclide therapy (PRRT) is a systemic therapy indicated for NETs characterized by high SSTR expression. To date, a tool for the early detection and treatment of NETs is missing, posing significant challenges for patients and physicians.
The primary goal of this research topic is to provide a valuable collection of cutting-edge research papers in the field of NETs. Precisely, we hope that it will highlight advancements in diagnostic imaging, new biomarkers, radiotracers, NET metabolism, and tumor microenvironment to foster progress toward personalized care for NET patients.
We invite Authors to submit original research articles, comprehensive reviews, case reports, and clinical studies that focus on, but are not limited to, the development of new therapeutic approaches including SSTR-based, targeted therapies, immunotherapies, ATMPs and chimeric antigen receptor (CAR) T cells. We also invite retrospective and prospective comparisons of current lines of therapy, liquid biopsy, diagnostic techniques, radiomics, and their role in monitoring NET progression. To conclude, papers elucidating specific aspects of NET metabolism and tumor microenvironment to drive NET tumorigenesis and resistance to therapy are welcome. We hope this research topic will gather studies featuring the most advanced and promising approaches for NET diagnosis and treatment paving the future of patients’ quality of life.
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords:
SSTR, radiotracers, PRRT, metabolism, diagnostics, Liquid-biopsy
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.